

# **COVID-19 Vaccine Provider Guidance Appendix**

Published January 5, 2021 | Updated June 25, 2021

Appendix 1 – EUA	Pfizer-BioNTech COVID-19 Vaccine   FDA
Fact Sheet for	
Recipients and	
Caregivers – Pfizer	
	Pfizer-BioNTech COVID-19 Vaccine   FDA
Appendix 2 – EUA	
Fact Sheet for	
Health Care	
Providers	
Administering	
Vaccine – Pfizer	
Appendix 3 – FDA	Pfizer-BioNTech COVID-19 Vaccine   FDA
Letter of	
Authorization –	
Pfizer	
Appendix 4 – V-safe	<u>V-safe Print Resources   CDC</u>
Information Sheet	
Appendix 5 – V-safe	<u>V-safe Print Resources   CDC</u>
poster	
Appendix 6 –	Product Information Guide
Product Information	
Guide for COVID-19	
Vaccines and	
Associated Products	
Appendix 7 – COVID-	https://files.nc.gov/covid/organization readiness checklist vfinal.docx
19 Vaccine	
Readiness Checklist	
Appendix 8 – Pfizer	Product Storage and Dry Ice   CVDvaccine-US.com (cvdvaccine-us.com)
Storage and	
Handling Checklist	
Appendix 9 – Pfizer	<u>Please see below</u>
Storage and	
Handling Overview	
Appendix 10 – Bulk	https://files.nc.gov/covid/recipient_bulk_upload_file.csv
upload template	
Appendix 11 – EUA	Moderna COVID-19 Vaccine   FDA
Fact Sheet for	
Recipients and	



Caregivers –	
Moderna	
	Madarna COVID 10 Vaccina   FDA
Appendix 12 – EUA Fact Sheet for	Moderna COVID-19 Vaccine   FDA
Providers –	
Moderna	
Appendix 13 –	https://www.modernatx.com/covid19vaccine-eua/providers/storage-handling.pdf
Storage and	
Handling Overview	
Moderna	
Appendix 14 -	<u>Please see below</u>
Sample/Template	
LHD Standing Order	
for Moderna COVID-	
19 Vaccine & Pfizer-	
BioN Tech COVID-19	
Vaccine	
Appendix 15 – FDA	Moderna COVID-19 Vaccine   FDA
Letter of	
Authorization for	
Moderna	
Appendix 16 – CDC	https://www.cdc.gov/vaccines/covid-19/info-by-
Moderna Standing	product/moderna/downloads/standing-orders.pdf
Order	
Appendix 17 – CDC	https://www.cdc.gov/vaccines/covid-19/info-by-
Pfizer Standing	product/pfizer/downloads/standing-orders.pdf
Order	
Appendix 18 – CDC	English: Vaccine Administration: Intramuscular (IM) injections: Adults 19 years of age
Pre-Vaccination	and older (cdc.gov)
Checklist English and	Spanish: https://www.cdc.gov/vaccines/covid-19/downloads/pre-vaccination-
Spanish Version for	screening-form-sp.pdf
COVID-19 Vaccines	
Appendix 21 –	https://www.cdc.gov/vaccines/covid-19/info-by-
COVID-19 Vaccine	product/moderna/downloads/temp-log-freezer-storage-celsius.pdf
Temperature Log	
Celsius	
Appendix 22 –	https://www.cdc.gov/vaccines/covid-19/downloads/refrigerator-storage-logger-
COVID-19 Vaccine	fahrenheit.pdf
Temperature Log	
Fahrenheit	
· am cimen	



Appendix 23 –	cvms recipient portal reset password job aid.pdf (nc.gov)
Recipient Portal	evins recipient portal reset password job ala.par (ne.gov)
Username	
Appendix 24 – CVMS	cvms recipient portal reset password job aid.pdf (nc.gov)
Recipient Portal	evins recipient portal reset password job ald.pdf (ne.gov)
Reset Password Job	
Aid	
Appendix 25 – CVMS	CVMS Offline Operations (Bottom of Page)
Offline Appointment	CVIVIS Offilite Operations (Bottom of Page)
Scheduling User	
Guide	
Appendix 26.1 –	https://files.nc.gov/covid/documents/vaccines/Deeper-Dive-Group-1.pdf
DEEPER DIVE:	Interpretation of the following deciments of the following decimes of t
Group 1. Health	
Care Workers &	
Long-Term Care	
Staff and Residents	
Appendix 26.2 –	https://files.nc.gov/covid/documents/vaccines/Deeper-Dive-Group-2.pdf
DEEPER DIVE:	Interpretation of the first of
Group 2 – Older	
Adults	
	https://files.ps.gov/covid/documents/vaccines/Docner Dive Crown 2 ndf
Appendix 26.3 –	https://files.nc.gov/covid/documents/vaccines/Deeper-Dive-Group-3.pdf
DEEPER DIVE:	
Group 3 – Essential	
Front-Line Workers	https://image.com/sate_d/g2002.gdf
Appendix 28 –	https://immunize.org/catg.d/p3082.pdf
Medical	
Management of	
Vaccine Reactions in	
Adults in a	
Community Setting	DC D'-NT COVID 40 V LEDA
Appendix 29 – FACT	Pfizer-BioNTech COVID-19 Vaccine   FDA
SHEET: Pfizer-	
BioNTech	Madawa COVID 10 Vasina LEDA
Appendix 30 – FACT	Moderna COVID-19 Vaccine   FDA
SHEET: Moderna	
Appendix 31 –	https://files.nc.gov/covid/documents/vaccines/Deeper-Dive-Group-4.pdf
DEEPER DIVE: Group	
4 – Adults at High	
Risk for Exposure	
and Increased Risk	
of Severe Illness	



Appendix 36 – Tip	https://files.nc.gov/covid/documents/vaccines/NC-Vaccine-Selfie-Video-Tip-
Sheet for Selfie	Sheet.pdf
Video on COVID-19	<u>onectipar</u>
Vaccination.	
Appendix 38 –	Please see below
COVID-19	Trease see below
Community Based	
Vaccination Events:	
Best Practices.	
Appendix 39 - CDC	Please see below
COVID-19	<u>Fiedse see below</u>
Vaccination Program	
Provider Agreement	
Appendix 40 –	Please see below
Vaccine Letter to	1 lease see below
County Leaders	
Appendix 41 – FDA	https://www.fda.gov/media/146303/download
Letter of	ittps://www.ida.gov/incula/140303/dowilload
Authorization for	
Janssen (Johnson &	
Johnson)	
Appendix 42 – EUA	https://www.fda.gov/media/146305/download
Fact Sheet for	nttps://www.ida.gov/media/140303/downioda
Recipients and	
Caregivers for	
Janssen (Johnson &	
Johnson) COVID-19	
Vaccine	
Appendix 43 – EUA	https://www.fda.gov/media/146304/download
Fact Sheet for	nteps.// www.ndd.gov/media/ 11050 i/ download
Health Care	
Providers	
Administering	
Vaccines for Health	
Care Providers	
Administering	
Vaccine for Janssen	
(Johnson & Johnson)	
COVID-19 Vaccine	
Appendix 44 - NC	https://files.nc.gov/covid/documents/guidance/vaccinations/Statewide-COVID-19-
State Health	Vaccine-Standing-Order.pdf
Director's Statewide	Table Containing Oracingar
211 COLOT 3 STATE WINC	



Standing Order for FDA Authorized	
COVID-19 Vaccine	
Administration of	
Pfizer-BioNTech and	
Moderna	
Appendix 45 - CVMS	<u>Please see below</u>
Organization Portal	
email template for	
vaccine providers to	
use to invite	
organizations	
Appendix 46 - CVMS	Please see below
Organization Portal	
email templates for	
organizations to use	
to inform employees	
Appendix 47 Janssen	https://www.cdc.gov/vaccines/covid-19/info-by-
(Johnson & Johnson)	product/janssen/downloads/janssen-storage-handling-summary.pdf
Storage and	
Handling Summary	
Tranaming Summary	
Appendix 48 Janssen	https://www.cdc.gov/vaccines/covid-19/info-by-
(Johnson & Johnson)	product/janssen/downloads/janssen-transportation-guidance.pdf
COVID-19 Vaccine	
Transporting	
Vaccine for	
Vaccination Clinics	
Held at Satellite,	
Temporary, or Off-	
Site Locations	
Appendix 49	https://www.cdc.gov/vaccines/covid-19/downloads/transport-temperature-log.pdf
Transport	
Temperature Log	
When Transporting	
Vaccine Refrigerated	
Temperatures	
Appendix 50 – NC	https://files.nc.gov/covid/documents/guidance/vaccinations/Statewide-Standing-
State Health	Order-COVID-19-Vaccine-Johnson-Johnson.pdf
Director's Statewide	



Standing Order for FDA Authorized COVID-19 Vaccine Administration of Janssen (Johnson & Johnson)	
Appendix 51 – Strategies to Fill COVID-19 Vaccine Appointments	Please see below
Appendix 52 – COVID-19 Vaccines- Pregnancy, Breastfeeding, and Fertility: What You Need to Know	https://covid19.ncdhhs.gov/media/2567/open
Appendix 53: Janssen (Johnson & Johnson) COVID-19 Vaccine Standing Orders (CDC)	https://www.cdc.gov/vaccines/covid-19/info-by-product/janssen/downloads/Janssen-Standing-Orders.pdf
Appendix 54: Pfizer COVID-19 Vaccine Approved for Teens (flyer)	https://covid19.ncdhhs.gov/media/2761/open
Appendix 55: Frequently Asked Questions About COVID-19 Vaccination (CDC)	https://www.cdc.gov/coronavirus/2019-ncov/vaccines/faq.html
Appendix 56: COVID- 19 Vaccination Coding and Billing Resources	https://covid19.ncdhhs.gov/media/3139/download?attachment
Appendix 57: COVID- 19 Vaccine Transport Guidance	https://covid19.ncdhhs.gov/media/3070/download?attachment



Appendix 58: COVID-19 Response Vaccine **Provider Toolkit** 

https://covid19.ncdhhs.gov/media/3142/download?attachment

# Appendix 9 - Pfizer Storage and Handling Overview

As of 12/6/2020

# **Shipping, Handling & Storage Overview**

Current as of December 16, 2020

Breakthroughs that change patients' lives The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by FDA, but has been authorized for emergency use by FDA under an Emergency Use Authorization to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older. The emergency use of this product is only authorize the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act the declaration is terminated or authorization revoked sooner.

Please see Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) including Full EUA Prescribing Information available at <a href="https://www.cod/accine.com">www.cod/accine.com</a>.



# **Change Log**

Version	History of Changes
01	Initial version
02	New content includes Overview of Shipping, Storage & Handling, Key Timing Considerations, and Re-icing Thermal Shipper     Modified temperature of Thermal shipper from -75+15°C (-103° to 5°F) to -90°C to -60°C (-130°F to -76°F)
03	Disclaimer language updated to reflect post-EUA mandatory language
04	Updated vial tray image

Breakthroughs that change patients' lives

The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by FDA, but has been authorized for emergency use by FDA under an Emergency Use Authorization to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.

Please see Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) including Full EUA Prescribing Information available at <a href="https://www.cvdvaccine.com">www.cvdvaccine.com</a>.



## Overview of Shipping, Storage & Handling

#### **Thermal Shipper Arrival**



The thermal shipper that the vaccine arrives in can be used as temporary storage, so long as dry ice is replenished upon receipt and every 5 days (up to 30 days).



The thermal shipper maintains a temperature range of -90°C to -60°C (-130°F to -76°F). Storage within this temperature range is not considered an excursion from the recommended storage condition.



#### Storage & Handling



Storage options for vials/trays include:

- 1. Ultra Low Temperature Freezer at -80° and -60°C (-112 to -76°F) for up to 6 months
- 2. Thermal Shipper at -90°C to -60°C (-130°F to -76°F) for up to 30 days from delivery, if replenished with dry ice upon receipt and every 5 days

  3. Refrigerator at 2 to 8 °C (35.6° to 46.4°F) for up to
- 120 hours (5 days)



Vial are glass and should be handled with care. Visual inspection prior to use should be carried out.



Vials should be protected from light and kept in the original packaging.



Vials should always remain upright in trays during storage.



#### **Returning Thermal Shipper**



The thermal shipping container may be used as temporary storage for up to 30 days from delivery, including temperature data logger.



The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by FDA, but has been authorized for emergency use by FDA under an Emergency Use Authorization to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.

Please see Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) including Full EUA Prescribing Information available at <a href="https://www.cvdvaccine.com">www.cvdvaccine.com</a>.



# **Direct Shipment to Points of Vaccination**

#### **Direct Shipments\* to Vaccination Center by Transport Courier**



Pfizer has designed a distribution model which is built on a flexible just in time system to ship the vaccine from manufacturing site and/or storage facility directly to the points of vaccination

#### **Temperature & Location Tracking During Transportation**



- Each thermal shipper has reusable GPS enabled temperature monitoring device which will be enabled when the shipper is packed.
- All shipments will be tracked via the onboard GPS monitoring device to ensure end-to-end distribution within required temperatures.
- Shipments will be executed under the management of Pfizer Quality processes and controls to ensure that upon ownership transfer, product has arrived under acceptable conditions.
- Temperature records of the shipments can be shared with upon request.

\*COVID Vaccine supply chain model is a drop ship direct from Pfizer manufacturing sites to the designated locations by the government.

Markets with no Pfizer commercial legal entity: Product ownership transfer at port of entry for governmental customer importation and in-market distribution

Breakthroughs that change patients' lives

The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by FDA, but has been authorized for emergency use by FDA under an Emergency Use Authorization to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.

Please see Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) including Full EUA Prescribing Information available at <a href="https://www.cvdvaccine.com">www.cvdvaccine.com</a>.

4




# **Product Packaging Overview**

#### **Vials**



- · 2 mL type 1 glass preservative free multi-dose vial (MDV)
- MDV has 0.45 mL frozen liquid drug product
- · 5 doses per vial after dilution

#### **Trays**



- · Single tray holds 195 vials
- 975 doses per tray
- A smaller tray, containing 25 vials (125 doses) is in development with estimated availability in early 2021

#### **Thermal Shipper**



- · Minimum 1 tray (975 doses) or up to 5 trays (4875 doses) stacked in a payload area of the shipper
- Payload carton submerged in dry ice pellets
- Thermal shipper keeps ULT -90°C to -60°C (-130°F to -76°F) up to 10 days if stored at 15°C to 25°C (5° to 77°F) temperatures without opening
- Thermal shippers are reusable and designed to be a temporary storage containers by replenishing dry ice.

Breakthroughs that change patients' lives The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by FDA, but has been authorized for emergency use by FDA under an Emergency Use Authorization to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.

Please see Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) including Full EUA Prescribing Information available at <a href="https://www.cvdvaccine.com">www.cvdvaccine.com</a>.



# **Key Timing Considerations**

TRAYS

3 MINS Open-lid vial trays, or vials trays containing less than 195 vials removed from frozen storage (< -60°C) may be at room temperature (< 25°C) for up to **3 minutes** for transfer between ultra low temperature environments or to remove vials for thawing or use.

5 MINS Closed-lid vial trays containing 195 vials removed from frozen storage (< -60°C) may be at room temperature (< 25°C) for up to **5 minutes** for transfer between ultra low temperature environments.

2 HRS After vial trays are returned to frozen storage following room temperature exposure, they must remain in frozen storage for at least **2 hours** before they can be removed again.



VIALS

Once an individual vial is removed from a vial tray at room temperature, it should not be returned to frozen storage and should be thawed for use.

.....



Breakthroughs that change patients' lives

The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by FDA, but has been authorized for emergency use by FDA under an Emergency Use Authorization to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.

Please see Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) including Full EUA Prescribing Information available at <a href="https://www.cvdvaccine.com">www.cvdvaccine.com</a>.


6



## **Re-icing Thermal Shipper**

#### Handling instructions

- Re-ice at a minimum of every 5 days (based on normal use). No restriction to number of re-icing. If box is left open for longer than 3 minutes, recommendation is to re-ice more frequently, as needed.
- If re-icing occurs and a holiday or weekend, plan ahead to re-ice the thermal shipping container.
- Thermal shipping container may be used as temporary storage for up to 30 days from delivery.
- Sites are required to maintain temperature monitoring



## Appendix 14 - Sample/Template LHD Standing Order for Moderna COVID-19 Vaccine & Pfizer-BioN Tech COVID-19 Vaccine

### Sample/Template LHD Standing Order for Moderna COVID-19 Vaccine

This Standing Order (SO) is for Registered Nurses (RN's) and Licensed Practical Nurses (LPN's) functioning as vaccination providers and practicing in local health departments in North Carolina to administer Moderna COVID-19 Vaccine authorized by the FDA through an Emergency Use Authorization (EUA) in accordance with the current Phase of Vaccination and conditions of this order.

#### **COVID-19 Testing**

### **Condition or** Situation

Patients (recipients of vaccine), 18 years of age and older, who present requesting and consent to Moderna COVID-19 Vaccine and who meet the vaccination criteria in the current Phase of Vaccination or any of the previous phases and have legal and decisional capacity to consent to the vaccine.

#### **Assessment Criteria**



# Assessment Criteria

Patients shall be vaccinated with Moderna COVID-19 Vaccine based on:

- 1. the conditions of this order
- 2. no history of complete 2-dose COVID-19 vaccination, regardless of brand.
- 3. meeting at least **one** of the criteria listed in the vaccination priority criteria defined by the current Phase of Vaccination or any previous phases indicated at <a href="https://covid19.ncdhhs.gov/vaccines">https://covid19.ncdhhs.gov/vaccines</a>.

#### Plan of Care

#### **Actions**

#### 1. Patient Education and Data Collection

- a. Prior to patients receiving the Moderna COVID-19 Vaccine, the nurse shall
  - i. Communicate to the recipient or their caregiver information consistent with the Fact Sheet for Recipients and Caregivers (and provide a copy or direct the individual to the website <a href="www.modernatx.com/covid19vaccine-eua">www.modernatx.com/covid19vaccine-eua</a> to obtain the Fact Sheet) prior to the individual receiving the Moderna COVID-19 Vaccine. Note: Providers need to ensure the most current version of this document by visiting <a href="https://www.modernatx.com/covid19vaccine-eua/">https://www.modernatx.com/covid19vaccine-eua/</a>. Information
    - <u>https://www.modernatx.com/covid19vaccine-eua/</u>. Information communicated must include:
    - FDA has authorized the emergency use of the Moderna COVID-19 Vaccine, which is not an FDA-approved vaccine.
    - The recipient or their caregiver has the option to accept or refuse the Moderna COVID-19 Vaccine.
    - The significant known and potential risks and benefits of the Moderna COVID-19 Vaccine, and the extent to which such risks and benefits are unknown.
    - Information about available alternative vaccines and the risks and benefits of those alternatives
  - ii. Providers should counsel Moderna COVID-19 vaccine recipients about expected local and systemic reactions.
  - iii. Provide anticipatory guidance regarding vaccination to the patient, which at a minimum shall include where, how, and when to obtain the second COVID-19 vaccination.

#### 2. COVID-19 Pre-Vaccination Procedures

- a. Review *Contraindications for Use of this Order* section of this standing order **before** administering the COVID-19 vaccine.
- b. Instruct patients with bleeding disorders or who take blood thinners to consult with their medical provider who is familiar with their bleeding risk to determine if the patient can receive an intramuscular injection with reasonable safety. Once the patient presents written documentation that the patient's medical provider advises that the patient can receive the vaccine, administer the vaccine using a 23 gauge or smaller caliber needle, followed by firm pressure on the site, without rubbing, for at least 2 minutes.
- c. Instruct patients who have received passive antibody therapy as treatment for COVID-19 that as a precautionary measure to avoid interference of the



- antibody treatment with vaccine-induced immune responses, COVID-19 vaccination will be deferred for at least 90 days.
- d. Instruct patients who are immunocompromised that the vaccine might be less effective than in someone who is immunocompetent.
- e. Instruct patients who are pregnant or lactating that these conditions are not contraindications to the current COVID-19 vaccine and may choose to get vaccinated. Available data on Moderna COVID-19 Vaccine administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy. Encourage women who are pregnant and receive the vaccine to Women who are vaccinated with Moderna COVID-19 Vaccine during pregnancy to enroll in the Pregnancy Exposure Registry by calling 1-866-MODERNA (1-866-663-3762). Data are not available to assess the effects of Moderna COVID-19 Vaccine on the breastfed infant or on milk production/excretion.
- f. Consent must be obtained from the patient or the patient's legally authorized representative. North Carolina, G.S. 90-21.5 authorizes a physician to accept the consent of a minor for medical health services for the prevention, diagnosis, or treatment of reportable communicable diseases. The statute states that any minor may give effective consent for the services described in the law. However, any given minor must still have the decisional capacity to consent.
- g. Don appropriate personal protective equipment (PPE) per Universal Precautions and to protect against the transmission of COVID-19.

#### 3. COVID-19 Vaccination Administration Procedures

- a. See the Dosage and Administration sections of the current Fact Sheet for Healthcare Providers Administering Vaccine for instructions for preparation and administration. This Fact Sheet may be updated as needed. For the most recent Fact Sheet, please see www.modernatx.com/covid19vaccineeua.
- Provide a vaccination card to the recipient or their caregiver with the date when the recipient needs to return for the second dose of Moderna COVID-19 Vaccine.
- c. Ensure that all <u>Mandatory Requirements for Moderna COVID-19 Vaccine</u>
  <u>Administration</u> Under Emergency Use Authorization as indicated in the
  <u>Fact Sheet for Healthcare Providers Administering Vaccine</u> are met.
- d. Provide the v-safe information sheet to vaccine recipients/caregivers and encourage vaccine recipients to participate in v-safe.
- e. The Moderna COVID-19 Vaccine is administered intramuscularly as a series of two doses (0.5mL each) 1 month apart.
- f. If the recipient has received one (1) previous Moderna COVID-19 Vaccine dose, the second dose of the same brand shall be administered.
- g. There is no information on the use of the Moderna COVID-19 Vaccine with other vaccines. Consult the medical provider for further orders. The vaccine series should be administered alone, with a minimum interval of 14 days before or after administration with any other vaccines. If mRNA



- COVID-19 vaccines are inadvertently administered within 14 days of another vaccine, doses do not need to be repeated for either vaccine.
- h. Patients with allergic reactions, including severe allergic reactions, NOT related to vaccines or injectable therapies (e.g., food, pet, venom, environmental, or latex allergies; oral medications) are NOT a contraindication or precaution to vaccination with currently authorized COVID-19 vaccine. CDC considers a history of severe allergic reaction (e.g., anaphylaxis) to any other vaccine or injectable therapy (e.g., intramuscular, intravenous, or subcutaneous) as a precaution but not a contraindication to vaccination. Individuals who have had severe allergic reactions to something, regardless of cause, shall be monitored for 30 minutes post COVID-19 vaccination. All other patients shall be monitored for 15 minutes post COVID-19 vaccination. See Contraindications for Use of this Order section below for contraindications regarding severe allergic reaction (e.g., anaphylaxis) to a previous dose of Moderna COVID-19 Vaccine or to any component of the vaccine.
- i. Document each patient's vaccine administration information in the patient's medical record and the COVID-19 Vaccine Management System (CVMS) following systems:
  - Medical Record: Within 24 hours of administering the vaccine, document pertinent patient history (including the Pre-Vaccination Form and consent), the date of administration, manufacturer, lot number, vaccination site and route, name, and title of the person administering the vaccine. Provide patient with a copy of their vaccination information: date of vaccination, product name/manufacturer, lot number, and name/location of the administering clinic or healthcare professional.
  - <u>CVMS</u>: Document within 24 hours after vaccine administration per system guidelines found at <a href="https://immunize.nc.gov/providers/covid-19training.htm">https://immunize.nc.gov/providers/covid-19training.htm</a>.
- j. Follow vaccine storage and handling, dosing, and administration required by the manufacturer.

#### Follow-up Follow up

- 1. Nurses administering Moderna COVID-19 Vaccine must report the following information associated with the administration of the vaccine in accordance with the *Fact Sheet for Healthcare Providers Administering Vaccine*:
  - Vaccine administration errors, whether associated with an adverse event or not
  - Serious adverse events (irrespective of attribution to vaccination)
  - Cases of Multisystem inflammatory syndrome in <u>adults</u>
  - Cases of COVID-19 that result in hospitalization or death
     Complete and submit reports to Vaccine Adverse Event Reporting System
     (VAERS) online at https://vaers.hhs.gov/reportevent.html or by calling 1-800-822-7967. The VAERS reports must include the words "Moderna COVID-19 Vaccine EUA" in the description section of the report.



 Nurses are required to follow the instructions in the letter issued by the Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for emergency use of Moderna COVID-19 Vaccine for the prevention of Coronavirus Disease 2019 (COVID-19) for individuals 18 years of age and older.

# Contraindications for Use of this Order

Do not give this vaccine if the following contraindication is present:

 Severe allergic reaction (e.g., anaphylaxis) to a previous dose of Moderna COVID-19 Vaccine or to any component of the vaccine.

### Criteria or Circumstances for Notifying Medical Provider

- 1. Allergic reaction: Call 911, implement medical emergency protocols and immediately notify the medical provider from the organization providing clinical supervision of the vaccination site/service.
- 2. Notify the medical provider if a patient has a moderate or severe acute illness, has a current COVID-19 infection, or is unaware of the COVID vaccine that they previously received.
- 3. Notify the medical provider if patient findings and/or conditions do not align with the instructions defined under, Plan of Care/Actions/2b.iii above.
- 4. Notify the Medical Provider from the organization providing clinical supervision of the vaccination site/service at any time there are questions or problems with carrying out this SO.

Approved by:	Date Approved:
Effective Date:	

**Expiration Date:** This standing order shall remain in force and effect for the duration of the state of emergency declared under Executive Order 116 unless otherwise modified, rescinded, or replaced.

#### **Legal Authority:**

Nursing Practice Act, N.C. General Statutes 90-171.20 (7)(f)(h)(i) & (8)(c)(c1.)(e.)(f.)

Sample Standing order for Pfizer-BioNTech COVID-19 Vaccine



Agency logo

### Sample/Template LHD Standing Order for Pfizer-BioNTech COVID-19 Vaccine

This Standing Order (SO) is for Registered Nurses (RN's) and Licensed Practical Nurses (LPN's) functioning as vaccination providers and practicing in local health departments in North Carolina to administer Pfizer-BioNTech COVID-19 Vaccine authorized by the FDA through an Emergency Use Authorization (EUA) in accordance with the current Phase of Vaccination and conditions of this order.

Situation and criping le	Patients (recipients of vaccine), 16 years of age and older, who present requesting and consent to Pfizer-BioNTech COVID-19 Vaccine and who meet the vaccination criteria in the current Phase of Vaccination or any of the previous phases and have egal and decisional capacity to consent to the vaccine.  Assessment Criteria  Patients shall be vaccinated with Pfizer-BioNTech COVID-19 Vaccine based on:  1. the conditions of this order
	Patients shall be vaccinated with Pfizer-BioNTech COVID-19 Vaccine based on: 1. the conditions of this order
	the conditions of this order
	<ol> <li>no history of complete 2-dose COVID-19 vaccination, regardless of brand.</li> <li>meeting at least one of the criteria listed in the vaccination priority criteria defined by the current Phase of Vaccination or any of the previous phases indicated at <a href="https://covid19.ncdhhs.gov/vaccines">https://covid19.ncdhhs.gov/vaccines</a>.</li> </ol>
	Plan of Care
Actions 1.	<ul> <li>a. Prior to patients receiving the Pfizer-BioNTech COVID-19 Vaccine, the nurse shall provide anticipatory guidance regarding vaccination to the patient, which at a minimum shall include: <ol> <li>i. Where, how, and when to obtain the second COVID-19 vaccination.</li> <li>ii. Pre-Vaccination Form for Pfizer-BioNTech COVID-19 Vaccine</li> <li>iii. Fact Sheet for Recipients and Caregivers – Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19) in Individuals 16 Years of Age and Older https://www.cvdvaccine-us.com/images/pdf/fact-sheet-for-recipients-and-</li> </ol> </li> </ul>
2.	Caregivers.pdf Note: Providers need to assure the most current version of this document by visiting <a href="http://www.cvdvaccine.com/">http://www.cvdvaccine.com/</a> 2. COVID-19 Vaccination Administration Procedures  a. Review Contraindications for Use of this Order section of this standing order before administering the COVID-19 vaccine.  b. Review the patient-completed Pre-Vaccination Form for Pfizer- BioNTech COVID-19 Vaccine.  i. For questions 1-3 and 5-9, if all responses are "no," then administer the vaccine per the SO.  ii. For questions 1-3, if there is a "yes" or "don't know" response, consult a medical provider (physician or advanced practice provider [nurse practitioner, certified nurse-midwife, or physician assistant]) for further orders.  iii. For question 4, if the patient has received a trial vaccine as a part of a COVID vaccine clinical trial, confirm that the trial sponsor determined it is feasible for the patient to receive additional doses. Consult the medical provider for further orders.  iv. If there is a "yes" for questions 5-9, follow the instructions below:  1. Instruct patients with bleeding disorders or who are taking

Sample/Template Standing Order for Pfizer-BioNTech COVID-19 Vaccine - December 19, 2020



Agency logo

- familiar with their bleeding risk to determine if the patient can receive an intramuscular injection with reasonable safety. Once the patient presents written documentation that the patient's medical provider advises that the patient can receive the vaccine, administer the vaccine using a 23 gauge or smaller caliber needle, followed by firm pressure on the site, without rubbing, for at least 2 minutes.
- Instruct patients who have received passive antibody therapy as treatment for COVID-19 that as a precautionary measure to avoid interference of the antibody treatment with vaccine-induced immune responses, COVID-19 vaccination will be deferred for at least 90 days.
- Instruct patients who are immunocompromised that the vaccine might be less effective than in someone who is immunocompetent.
- 4. Instruct patients who are pregnant or lactating that these conditions are not contraindications to current COVID-19 vaccine and may choose to get vaccinated. Educate the patient that there are currently no data available on the safety of COVID-19 vaccines in pregnant women, but studies and results are expected soon. Data demonstrate that while the absolute risk is low, pregnant women with COVID-19 have increased risk of severe illness. Also educate patients that there is no data available for lactating women on the effects of mRNA vaccines.
- c. Consent must be obtained from the patient or the patient's legally authorized representative. North Carolina, G.S. 90-21.5 authorizes a physician to accept the consent of a minor for medical health services for the prevention, diagnosis, or treatment of reportable communicable diseases. The statute states that any minor may give effective consent for the services described in the law. However, any given minor must still have the decisional capacity to consent.
- d. Before administering the COVID-19 vaccination, don appropriate personal protective equipment (PPE) per Universal Precautions and to protect against the transmission of COVID-19.
- e. Choose the correct needle gauge, needle length, and injection site for persons:
  - 16 through 18 years of age: 1-inch needle, administered in the deltoid muscle of the arm.
  - ii. 19 years of age and older: See table in Appendix 1 below.
- f. Mix, observing sterile technique, Pfizer-BioNTech COVID-19 Vaccine with 0.9% sodium chloride (normal saline, preservative-free) diluent according to the manufacturer's instructions. Follow manufacturer's guidance for storing/handling mixed vaccine.
- g. Administer 0.3 mL Pfizer-BioNTech COVID-19 Vaccine by intramuscular (IM) injection in the deltoid muscle of the arm. If contraindications exist to using the deltoid, the anterolateral thigh also can be used.
- h. This vaccine is administered in a 2-dose series. Separate doses by at least 21 days. If the 2nd dose Pfizer vaccine was given 17 or more days after the 1st dose, then do not repeat a 2nd dose.



# <u>Appendix 32 - Sample talking points and scripts for fielding incoming requests to local health</u> departments, hospitals, and health systems.

#### (1) General information about the vaccine

- Tested, safe and effective vaccines will be available to all who want to get vaccinated, but supplies are currently limited and will continue to be for the next few months.
  - To save lives and slow the spread of COVID-19, independent state and federal public health advisory committees recommend first protecting health care workers caring for patients with COVID-19, people who are at the highest risk of being hospitalized or dying, and those at high risk of exposure to COVID-19
  - The following regularly updated resources should be used to respond to general information inquiries about the vaccine:
    - o NCDHHS COVID-19 Vaccine Frequently Asked Questions (English / Spanish)
    - NCDHHS Presentation COVID-Vaccination 101 (English / Spanish)
    - o NCDHHS Flyer on COVID-19 Vaccines (English / Spanish)

#### (2) Information about how to get vaccinated

- North Carolina's updated groups are as follows:
  - o Group 1: Health care workers and Long-Term Care staff and residents
  - o Group 2: Older Adults
  - Group 3: Front-line essential workers
  - o Group 4: Adults at high risk for exposure and at increased risk of severe illness
  - o Group 5: Everyone who wants a safe and effective COVID-19 vaccination
- The following resources should be used to respond to inquiries about NCDHHS vaccination phases
  - Infographic of Vaccine Phases (<u>English</u> / <u>Spanish</u>)
  - Deeper Dive: Group 1 (English / Spanish)
  - Deeper Dive: Group 2 (English / Spanish)
  - o Deeper Dive: Group 3 (English/ Spanish)
- Key vaccine messages for 65+ population
  - Anyone 65 years or older may now get their first COVID-19 shot.
  - Vaccine supplies are limited, and you may have to wait, but you have one of the first spots to take your shot.
  - Most doctors can't provide COVID-19 shots in their offices, so work with local health department or hospital to get your shot.
  - Take your shot to get life back to when we could be with family and friends and come together at events and celebrations.
  - Take your shot to gain the peace of mind that you're protected and you're protecting others from getting sick from COVID-19



#### (3) Customer relations.

The following talking points can be used when fielding questions or concerns from the public on various topics related to the vaccine.

- Talking points to set expectations about vaccine availability
  - A vaccine will be available to all who want it, but right now vaccine supply is very limited. There
    is not enough vaccine supply for everyone to get vaccinated right away.
  - The federal government decides how many COVID-19 vaccine doses each state gets based on the state's population of people ages 18 and up and notifies our state each week of how much vaccine we will receive.
- Talking points to respond to dissatisfaction about the phases of vaccine prioritization
  - Independent state and federal public health advisory groups have determined that the best way to fight COVID-19 is to start first with vaccinations for those most at risk, and then reach more people as vaccine supply increases throughout 2021.
  - North Carolina, like many other states, aligned its vaccine prioritization with federal recommendations and had input from an external Advisory Committee.
- Talking points to respond to mistrust and vaccine hesitancy
  - The vaccines are tested, safe, and effective.
    - More than 70,000 people volunteered in clinical trials for two vaccines (Pfizer and Moderna) to see if they are safe and work to prevent COVID illness. Volunteers included Black/African Americans, Hispanic LatinX, Asians and others.
    - Vaccines were found to help prevent COVID-19 and are effective in preventing hospitalization and death, with no serious safety concerns noted in the clinical trials.
    - The U.S. Food and Drug Administration (FDA) makes sure the vaccines are safe and can prevent people from getting COVID-19. Like all drugs, vaccine safety continues to be monitored after they are authorized for use.
  - You cannot get COVID-19 from the vaccine.
    - You may have temporary reactions like a sore arm, headache or feeling tired and achy for a day or two after receiving the vaccine.

#### (4) Example auto-response message:

Thank you for your inquiry about COVID-19 vaccination. For up-to-date information about vaccination in North Carolina, please visit yourspotyourshot.nc.gov.

As of **<insert date>**, we are currently vaccinating the following groups:

- · Health care workers with in-person patient contact
- Health care workers administering vaccine in initial vaccine groups
- Long-term care staff and residents—people in skilled nursing facilities and in adult, family and group homes
- Anyone 65 years or older, regardless of health status or living situation
- Essential workers

If you fall into one of these categories, please contact **<insert local vaccine number>** to schedule an appointment for your spot in line -OR- **<insert local vaccination schedule details here>**.



Remember: you have a spot, take your shot!

### (5) Example automated phone messages\*:

#### **Automated Message, part 1:**

Thank you for calling **<insert organization name>**. *Para español, oprima* **<insert number for Spanish-version of message>**. For questions related to the COVID-19 vaccine, please press **<insert number>**. **<Insert remainder of typical outgoing automated message here>**.

Automated Message, part 2:	
	_>, we are actively vaccinating for COVID-19 according to Human Services guidelines, which are available at
•	al workers may now get vaccinated. Supplies are very e 65 or older or an essential worker, <b><insert b="" instructions<=""></insert></b>

We are also still vaccinating all health care workers with in-person patient contact. If you are a member of this group, **<insert instructions here>**. We are also still vaccinating residents and staff in nursing homes and other long term are facilities.

\*Local health departments would need to use part 1 in their opening outgoing message and then have an extension for part 2. The message in Part 2 would need to be updated weekly.

(back to top)



### Appendix 33 - Vaccine patient outreach template for providers.

Health care providers can use the following email/letter template to share important information about COVID-19 vaccines with patients, especially patients 65 years or older who are eligible to receive the vaccine as part of Group 2. The template is intended to inform patients about vaccines and how they can get a vaccine. It can be customized to fit your community and can be used in multiple formats, such as electronic health record messages, your website, patient e-newsletters, etc.

#### **Template For Health Care Provider Outreach to Patients:**

#### Dear patients,

Vaccines are your best protection against COVID-19. Beginning on **<insert date on or after January XX<sup>th</sup>>**, anyone age 65 years or older and essential workers can receive a safe vaccine to protect you from getting COVID-19.

Vaccine supplies are limited, and you may have to wait, but you have one of the first spots to take your shot.

We strongly recommend you get the vaccine. The COVID-19 vaccine is our best shot to help us all get back control of our lives and back to the people and places we love. Vaccines were found to help prevent COVID-19 and are effective in preventing hospitalization and death, with no serious safety concerns noted in the clinical trials. You cannot get COVID-19 from the vaccine. You may have temporary reactions like a sore arm, headache or feeling tired and achy for a day or two after receiving the vaccine. You will need a second shot, at least 3 tor 4 weeks after the first shot, to build up your immunity. You can get your shot at no cost.

Vaccines are being offered at <insert name of hospital/health system that is an enrolled vaccine provider>. Here are your next steps for getting vaccinated:

#### [Insert all options that are available to your patients]:

- Go to <insert website> and call one of the local vaccine providers on the list; OR
- Respond to this message indicating your interest in being vaccinated against COVID-19. The COVID-19 vaccination team will contact you about when and where you can get vaccinated; OR
- Schedule a vaccination appointment by calling <insert phone number>; OR
- Schedule a vaccination appointment by taking the following steps in your electronic chart <insert instructions>; OR
- Let us know if you will need assistance with arranging for transportation to this appointment
- Attend walk-in hours at the following times and locations: <insert information>
  - Note: Exercise caution when using this option due to the potential for crowded vaccination events or prolonged wait time for elderly patients
- Get your vaccine through drive-through or curbside events at the following times and locations: <insert information>; OR
- Visit our website for upcoming vaccine events we will be hosting in the community at <insert link>; OR
- <Insert any other ways people can get the vaccine>



If you have questions about the vaccine, you can take the following steps:

- Visit the NCDHHS website for more information about the vaccine: YourSpotYourShot.nc.gov
- Call our office at <insert phone number> during <insert hours>
- Send us a message in your electronic chart
- <Insert any other ways your patients can learn about the vaccine or ask questions>

(back to top)



# Appendix 34 - Letter template to conduct outreach to primary care providers for vaccinations for Older Adults in Group 2 (for Local Health Departments).

Local Health Departments can use this email/letter template below for outreach to primary care providers who may have patients 65 years or older. Local Health Departments should focus their outreach efforts with primary care providers who serve historically marginalized populations and who are not affiliated with a hospital or health system that is an enrolled vaccine provider. The letter template can be customized to fit your community.

Dear providers,

Beginning on <insert date on or after January 14<sup>th</sup>>, your patients in Groups 1, 2 and 3 will be eligible to take a safe vaccine to protect them from getting COVID-19.

Vaccines are currently being offered for the following populations:

- Group 1: Health care workers and Long-Term Care staff and residents.
- Group 2: Older Adults
- Group 3: Frontline Essential Workers

If your practice is not yet an enrolled vaccine provider that has received a vaccine allocation, our agency is prepared to help support vaccinations for your staff and your patients who fall into these groups. One strategy for this partnership is for you to identify your eligible staff and your patients who are eligible for the COVID-19 vaccine in Group 1, 2 and 3. We can then work with you to provide your staff and patients with instructions to get vaccinated in as timely a manner as possible.

Some potential scenarios for how primary care providers are working with vaccine providers to get their staff and patients vaccinated are described below:

- Scenario 1: PCP is the main point of contact with patients for identification, outreach, scheduling, and communication. The PCP completes a spreadsheet provided by the vaccine provider that includes information for all eligible patients. The assigned vaccine provider will provide a scheduling spreadsheet with available dates/times for vaccine appointments, along with other patient logistics. PCP then fills available appointment slots and sends patient reminders and other needed patient communication. The PCP and vaccine provider may share vaccine clinic staffing responsibilities.
- Scenario 2: Vaccine provider is the primary point of contact with patients. PCP supports patient identification and outreach and provides any necessary patient contact information in a spreadsheet provided by the vaccine provider. The assigned vaccine provider communicates directly with eligible patients, manages scheduling, and provides necessary logistics for vaccination.
- Scenario 3: Vaccine provider works with PCP practices to offer vaccination clinic opportunities for groups of smaller practices or a single large practice. PCP and vaccine provider may share vaccine clinic staffing responsibilities.



# <u>Appendix 35 - Sample content for communicating with patients about COVID-19 vaccines</u> (for LHDs, hospitals/health systems, or PCPs).

A COVID-19 Vaccination Communications Toolkit is available and regularly updated at yourspotyourshot.nc.gov. The page is also available in Spanish: covid19.ncdhhs.gov/vacuna.

We encourage vaccine and health care providers to use and share the following vaccine resources with your patients and networks:


- Infographic of COVID-19 Vaccine Phases (<u>English</u> / <u>Spanish</u>)
- Deeper Dive: Group 1 (<u>English</u> / <u>Spanish</u>)
- Deeper Dive: Group 2 (English / Spanish)
- Deeper Dive: Group 3 (English/ Spanish)
- Flyer on COVID-19 Vaccines (English / Spanish)
- Flyer on COVID-19 Vaccines 65 years or older (English / Spanish)
- Postcard (4x6, two sided) (<u>English</u> / Spanish Coming)
- Handout (8x11) (English / Spanish Coming)
- Presentation COVID-Vaccination 101 (English / Spanish)
- COVID-19 Vaccine Frequently Asked Questions (English / Spanish)
- Videos on COVID-19 Vaccine Rollout
  - NCDHHS Secretary Mandy Cohen shares information on the COVID-19 vaccine rollout plan (30-second)
  - NCDHHS Deputy Secretary Ben Money shares information on the COVID-19 vaccine rollout plan (<u>link</u>)
- Videos for Long-Term Care
  - North Carolina long-term care workers share their reason for taking the newly developed COVID-19 vaccine (90-second, 60-second, 30-second)
  - NCDHHS Secretary Mandy Cohen shares information on the COVID-19 vaccine rollout plan long-term care facility workers (60-second)
  - NCDHHS Secretary Mandy Cohen shares information on the COVID-19 vaccine rollout plan for families of long-term care residents (link)
  - NCDHHS Deputy Secretary Ben Money shares information on the COVID-19 vaccine rollout plan for long-term care facilities (60-second, 30-second)
- NC Vaccine Selfie Video Tip Sheet (English / Spanish Coming)

(back to top)



### <u>Appendix 38 - COVID-19 Community Based Vaccination Events: Best Practices.</u>

#### Why Vaccinate in the Community?



Example of a hot spot map to guide testing site location

For North Carolina to successfully meet its goal of vaccinating as many people as quickly as possible given the limited supply of vaccines, we must mobilize community based vaccination events. To meet North Carolina's equally important goal of ensuring equity to access to the vaccine, intentional actions should be taken in the planning of those mass vaccination events.

**Best Practice**: Hold vaccination events in settings that will enable prioritized and historically marginalized populations to access vaccination. Well established patterns of COVID-19 infection continue to demonstrate that Black/African American and LatinX/Hispanic populations are disparately impacted by the pandemic.

While there is probably not a wrong place to do community mass vaccinations, there are certainly some locations with more potential to support and protect historically marginalized populations who have disproportionately borne the burden of the COVID-19 pandemic. Use existing data sources to identify specific locations with a high concentration of low-income earners, subsidized housing, concentrations of multiple chronic illness, etc. You can also use the <a href="MCDHHS">MCDHHS</a> Social Determinants of Health Interactive Map to identify locations where they reside.

**Transportation Assistance** - Ensuring access to transportation in an important element for equity. Local transit agencies serve all 100 North Carolina counties and funding has been given to local transit agencies to help provide this support. People who need transportation assistance to a COVID-19 vaccine should reach out to their local transit agency which are listed here <a href="NC\_Public\_Transit.pdfOpen PDF">NC\_Public\_Transit.pdfOpen PDF</a> (ncdot.gov). As you are planning an vaccination event, publicizing this resources can increase access to those with limited transportation.

**No charge to patients/vaccine recipients** - To receive free supplies of the COVID-19 vaccine(s), vaccine providers must sign the provider agreement with the U.S. Government. Under the agreement, all providers must vaccinate individuals regardless of whether they have health insurance coverage or what type of coverage they have, and all providers are prohibited from balance billing or otherwise charging vaccine recipients.



**Residency requirements -** The Centers for Disease Control and Prevention has instructed states that this is a federal vaccine bought with federal funding. Hence, jurisdictions should not put restrictions on administering vaccinations to non-residents, as long as those persons meet the current eligibility criteria. This applies to both county and state residency.

**Proof of identification** is not required to schedule an appointment or to receive a vaccine. Individuals can self-attest to the criteria (e.g., age, job role, health status, living situation) that they qualify for in eligible priority groups.

#### **Creating the Community Based Vaccination Team**

Community based vaccination clinics will be successful if championed by a leadership team that includes the local health department (LHD), health care providers such as community health centers (also known as federally qualified health centers or FQHCs), hospitals, private and hospital-based providers and community partners. The CDC link for full planning information can be found at https://www.cdc.gov/vaccines/hcp/admin/mass-clinic-activities/index.html.

It is important to note that, for many people, their first experience with the public health system may be the vaccine event and creating an environment that instills confidence and inspires trust is crucial. It is essential that partners who are trusted within their communities are part of the leadership team, such as faith, community service organizations and other non-profit leaders.

There are other strategies that can ensure we are vaccinating equitably – partner with local organizations with trusted relationships and help them facilitate sign-up for your events or compile waiting lists for your next clinic or event. Think about how an online-only sign-up method impacts access and consider instead filling first appointments by calling individuals compiled on a waiting list created by a key community partner. Hold vaccine clinics in historically marginalized communities, partnering with the community to organize and bring-on volunteers.

### **Staffing**

A large-scale immunization administration event requires three main types of personnel:

- Healthcare professionals authorized to provide vaccinations and who can respond to medical emergencies, including severe allergic reactions and anaphylaxis.
- Healthcare staff with knowledge about vaccines and experience handling vaccines and preparing vaccine doses.
- Nonmedical personnel to fill a variety of support roles, including check-in and registration, data entry, logistics, traffic flow, safety personnel.

These events can be staffed by your employees or community volunteers.



#### **Training**

Train your staff and volunteers with as much lead time as possible by using the online training modules. Trainings can be recorded and then reviewed online as new members are brought onboard:

- CDC COVID-19 Vaccine Training Modules: https://www2.cdc.gov/vaccines/ed/covid19/
  - This is a series of 3 online trainings that your medical professionals need to complete prior to assisting during an event. They will receive continuing education credit for completing the modules.
- Z-Track IM Injection Method: https://www.youtube.com/watch?v=DBHnd3N-5Ns
- Example of a training/welcoming video for volunteers from Orange County.
- https://www.youtube.com/watch?v=kenVwQGeDUg&feature=youtu.be
- Many counties are using online portals to coordinate their volunteers. Some portal examples are Calendy, Sign-Up Genius, chat lines on websites and MyChart. Here is an example of the Orange County Volunteer Portal. <a href="https://www.signupgenius.com/go/10c0d49aaad2aabfac07-covid">https://www.signupgenius.com/go/10c0d49aaad2aabfac07-covid</a>

#### Vaccine Guidance

In order for all staff to give consistent answers to any questions related to the vaccines, use the following guidance:

https://files.nc.gov/covid/documents/COVID-19-Vaccine-Update.pdf and

https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html

## **Personal Protective Equipment (PPE)**

Personal Protective Equipment (PPE) is needed for the staff vaccinating and in close contact with persons being vaccinated. It is a Best Practice to provide masks to everyone attending an event where individuals are to be vaccinated and emphasize how to correctly use them (i.e., cover the nose and mouth). Gloves and hand sanitizer are other common items that you will need to provide. Organizations should order PPE through their regular supply chains, if possible. Organizations can also request and access PPE through the <u>state-maintained PPE supply site.</u>

#### **Community Mass Vaccination ABCs**

### Advance Planning

Perhaps the most important part of a successful mass vaccination is the coordination and clear identification of all partners early in the process. A site visit in advance of the vaccination event provides the ability to plan for missing requirements, such as water, Wi-Fi, shelter and to layout the traffic patterns. The CDC has a checklist to take you through each step of the process and can be found here:

https://www.izsummitpartners.org/content/uploads/2019/02/off-site-vaccination-clinic-checklist.pdf

#### Access to the Internet



Accessing Wi-Fi can be crucial for the medical partner to register patients, whether through expanded network near the testing spot or adequately powered hotspot. It is a Best Practice for patients and administered vaccine doses to be entered into CVMS at the time of vaccination to optimize data collection for ongoing follow up and to show real time vaccination data. Using tablets onsite allows you to enter the data in real-time. Allow for extra tablets so that charging can occur on a rotational basis and provide heavy-duty outdoor extension cords for this equipment.

#### **Basic Needs**

Staff at vaccination sites may be exposed to the elements for long periods depending on the length of time the event is scheduled. There are certain basic needs that should be attended to thoughtfully, to include at a minimum:

- Toilet facilities (portable rentals if indoor facility is not close)
- Handwashing facilities (portable station if indoor facility is not close)
- Eating location with seats and cover away from vaccination or patient locations
- Shelter in the form of several secure, heavy-duty tents to endure heavy wind, rain and sun; cover the medical team, health department educators, vaccinators, etc., and their electronics; and provide adequate space to social distance. You should plan on at least one tent for each workstation including the traffic monitors and patient monitoring stations.
- Basic beverage and food provision (consider coffee/pastries at start up, bottled water all day, lunch delivered to site)

#### **Clear Identification of Vaccination Site Staff**

Team members need to be easily and clearly identified. Without a standardized identification (could be as simple as a colored sticky name tag on the chest), it is difficult to tell who is there to be vaccinated and who is a volunteer since everyone has different face coverings. Clear identification keeps the environment safe for privacy (if not well identified, others can access areas intended only for staff) and makes it easy for people presenting for vaccination to know who can answer their questions. One thing to consider is that depending on the community you are vaccinating; fear of authorities may deter people from coming to a testing event. Avoiding highly uniformed staff and instead wearing more casual street clothes creates a safer-feeling environment at times.





Orange County team working with a rural faith-based community partner.

#### Clear Incident Command on the Ground

Identify the Incident Commander of the operation before the event begins. This individual should be empowered to make critical decisions in the moment, such as those related to vaccination parameters, complications in logistics, conflicts and environmental threats. This person should have the contact information of the executive leaders from each organization participating in the vaccination event and feel comfortable reaching out immediately for support if needed. Finally, this person needs to make themselves known and available for the entire testing event.

#### **Community Engagement and Promotion**

Advanced planning also allows the team to provide promotional material and communication to alert the community about the event. Local media outlets are often willing to assist in promoting an event; additionally, bringing in non-medical partners to volunteer at the event can lead to great attendance and engagement. It is important to provide in advance clearly defined roles for volunteers, schedules, written instructions for safety and a designated point of contact (such as the Incident Commander) to address questions.

- Anticipatory guidance and health education should be provided by the patient monitors during the observation period. This allows the individual to ask any questions they may have. The appointment for the second dose should be done at the time of the first vaccination appointment and can be done while you are reviewing the patient information sheet with the individual. <a href="https://files.nc.gov/covid/documents/COVID-19-Vaccine-Update.pdf">https://files.nc.gov/covid/documents/COVID-19-Vaccine-Update.pdf</a>
- Media liaisons on site can be helpful as often the local media becomes interested in the vaccination event,
  especially if publicity was effective in advance. Identifying one person at the site to monitor for and manage
  media requests is important. If media can be scheduled in advance to arrive and complete interviews before the
  event there is less concern of patient privacy compromise or creating discomfort for community members who
  would like to be vaccinated.

#### Thoughts from the Field

- Use appointments with block shifts to spread out the volume and shorten wait times. For example, based on your staffing, you could anticipate 20 patients an hour.
- Use carpooling or personal transportation to bring elderly to the mobile site
- Use individuals from your community partner to work the initial greeting station so that individuals see a familiar face
- Flexibility on the ground is key so that you can respond to issues as they arise
- Schedule 2nd appointment while they are in the patient monitoring phase
- Have extra staff or runners available
- Virtual translators
- Allow onsite registration
- EMS on call
- Embrace technology; use apps or online portals to schedule appointments both for patients or your volunteer team
- Paper forms for back-up



- If you have both types of vaccines available on a given day, use the Pfizer types first.
- One way in, one way out traffic pattern

•

If a community is having difficulty executing a community vaccination event, NCDHHS is willing to help connect and direct a vaccination strategy, as well as making connections to forge partnership at the local level. For answers to questions about COVID-19 resources, visit the <a href="North Carolina COVID-19 Information Hub.">North Carolina COVID-19 Information Hub.</a>

<u>Appendix 39 - CDC COVID-19 Vaccination Program Provider Agreement (See next page)</u>



# SAMPLE

# **CDC COVID-19 Vaccination Program Provider Agreement**



#### Please complete Sections A and B of this form as follows:

The Centers for Disease Control and Prevention (CDC) greatly appreciates your organization's (Organization) participation in the CDC COVID-19 Vaccination Program. Your Organization's chief medical officer (or equivalent) and chief executive officer (or chief fiduciary)—collectively, Responsible Officers—must complete and sign the CDC COVID-19 Vaccination Program Provider Requirements and Legal Agreement (Section A). CDC COVID-19 Vaccination Program Provider Profile Information (Section B) must be completed for each vaccination Location covered under the Organization listed in Section A.

# Section A. COVID-19 Vaccination Program Provider Requirements and Legal Agreement

ORGANIZATION IDENTIFICATION			
Organization's legal name:			
Complete in CVMS			
Number of affiliated vaccination locations covered by this agreement:			
Organization telephone number: Email (must be monitored and will serve as COVID-19 Vaccination Program):		s dedicated contact method for the	
Organization address:			
RESPONSIBLE OFFICERS			
For the purposes of this agreement, in addition to Organization, Responsible Officers named below will also be accountable for compliance with the conditions specified in this agreement. The individuals listed below must provide their signature after reviewing the agreement requirements.			
Chief Medical Officer (or Equivalent) Information	n		
Last name Complete in CVMS	First name		Middle initial
Title	Licensure (s	tate and number)	
Telephone number:		Email:	
Address:			
Chief Executive Officer (or Chief Fiduciary) Information			
Last name Complete in CVMS	First name		Middle initial
Telephone number:	Email:		
Address:			

9/14/2020 Page **1** of **8** 33



# SAMPLE CDC COVID-19 Vaccination Program Provider Agreement

AGRE	EMENT REQUIREMENTS				
Lunde	erstand this is an agreement between Organization and CDC. This program is a part of collaboration under				
the re	the relevant state, local, or territorial immunization's cooperative agreement with CDC.				
To red	eive one or more of the publicly funded COVID-19 vaccines (COVID-19 Vaccine), constituent products,				
and a	ncillary supplies at no cost, Organization agrees that it will adhere to the following requirements:				
	Organization must administer COVID-19 Vaccine in accordance with all requirements and				
1.	recommendations of CDC and CDC's Advisory Committee on Immunization Practices (ACIP). <sup>1</sup>				
	Within 24 hours of administering a dose of COVID-19 Vaccine and adjuvant (if applicable), Organization				
	must record in the vaccine recipient's record and report required information to the relevant state,				
	local, or territorial public health authority. Details of required information (collectively, Vaccine-				
	Administration Data) for reporting can be found on CDC's website. <sup>2</sup>				
	Organization must submit Vaccine-Administration Data through either (1) the immunization				
2.	information system (IIS) of the state and local or territorial jurisdiction or (2) another system designated				
	by CDC according to CDC documentation and data requirements. <sup>2</sup>				
	Organization must preserve the record for at least 3 years following vaccination, or longer if required by				
	state, local, or territorial law. Such records must be made available to any federal, state, local, or				
	territorial public health department to the extent authorized by law.				
	Organization must not sell or seek reimbursement for COVID-19 Vaccine and any adjuvant, syringes,				
3.	needles, or other constituent products and ancillary supplies that the federal government provides				
	without cost to Organization.				
	Organization must administer COVID-19 Vaccine regardless of the vaccine recipient's ability to pay				
4.	COVID-19 Vaccine administration fees.				
	Before administering COVID-19 Vaccine, Organization must provide an approved Emergency Use				
5.	Authorization (EUA) fact sheet or vaccine information statement (VIS), as required, to each vaccine				
	recipient, the adult caregiver accompanying the recipient, or other legal representative.				
6.	Organization's COVID-19 vaccination services must be conducted in compliance with CDC's Guidance				
	for Immunization Services During the COVID-19 Pandemic for safe delivery of vaccines. <sup>3</sup>				
	Organization must comply with CDC requirements for COVID-19 Vaccine management. Those				
	requirements include the following:				
	a) Organization must store and handle COVID-19 Vaccine under proper conditions, including				
	maintaining cold chain conditions and chain of custody at all times in accordance with the				
-	manufacturer's package insert and CDC guidance in CDC's Vaccine Storage and Handling Toolkit <sup>4</sup> ,				
7.	which will be updated to include specific information related to COVID-19 Vaccine;				
	b) Organization must monitor vaccine-storage-unit temperatures at all times using equipment and				
	practices that comply with guidance located in CDC's Vaccine Storage and Handling Toolkit <sup>4</sup> ;				
	c) Organization must comply with each relevant jurisdiction's immunization program guidance for				
	dealing with temperature excursions;				

This agreement expressly incorporates all recommendations, requirements, and other guidance that this agreement specifically identifies through footnoted weblinks. Organization must monitor such identified guidance for updates. Organization must comply with such updates.

9/14/2020 Page **2** of **8** 

34

L

<sup>&</sup>lt;sup>1</sup> https://www.cdc.gov/vaccines/hcp/acip-recs/index.html

<sup>&</sup>lt;sup>2</sup> https://www.cdc.gov/vaccines/programs/iis/index.html

<sup>&</sup>lt;sup>3</sup> https://www.cdc.gov/vaccines/pandemic-guidance/index.html

<sup>&</sup>lt;sup>4</sup> https://www.cdc.gov/vaccines/hcp/admin/storage-handling.html



# SAMPLE

# **CDC COVID-19 Vaccination Program Provider Agreement**

d) Organization must monitor and comply with COVID-19 Vaccine expiration dates; and		
e) Organization must preserve all records related to COVID-19 Vaccine management for a minimum of		
3 years, or longer if required by state, local, or territorial law.		
Organization must report the number of doses of COVID-19 Vaccine and adjuvants that were unused, spoiled, expired, or wasted as required by the relevant jurisdiction.		
Organization must comply with all federal instructions and timelines for disposing COVID-19 vaccine and adjuvant, including unused doses. <sup>5</sup>		
Organization must report moderate and severe adverse events following vaccination to the Vaccine  Adverse Event Reporting System (VAERS). <sup>6</sup>		
Organization must provide a completed COVID-19 vaccination record card to every COVID-19 Vaccine recipient, the adult caregiver accompanying the recipient, or other legal representative. Each COVID-19 Vaccine shipment will include COVID-19 vaccination record cards.		
<ul> <li>a) Organization must comply with all applicable requirements as set forth by the U.S. Food and Drug Administration, including but not limited to requirements in any EUA that covers COVID-19 Vaccine.</li> <li>b) Organization must administer COVID-19 Vaccine in compliance with all applicable state and territorial vaccination laws.</li> </ul>		

By signing this form, I certify that all relevant officers, directors, employees, and agents of Organization involved in handling COVID-19 Vaccine understand and will comply with the agreement requirements listed above and that the information provided in sections A and B is true.

The above requirements are material conditions of payment for COVID-19 Vaccine-administration claims submitted by Organization to any federal healthcare benefit program, including but not limited to Medicare and Medicaid, or submitted to any HHS-sponsored COVID-19 relief program, including the Health Resources & Services Administration COVID-19 Uninsured Program. Reimbursement for administering COVID-19 Vaccine is not available under any federal healthcare program if Organization fails to comply with these requirements with respect to the administered COVID-19 Vaccine dose. Each time Organization submits a reimbursement claim for COVID-19 Vaccine administration to any federal healthcare program, Organization expressly certifies that it has complied with these requirements with respect to that administered dose.

Non-compliance with the terms of Agreement may result in suspension or termination from the CDC COVID-19 Vaccination Program and criminal and civil penalties under federal law, including but not limited to the False Claims Act, 31 U.S.C. § 3729 et seq., and other related federal laws, 18 U.S.C. §§ 1001, 1035, 1347, 1349.

By entering Agreement, Organization does not become a government contractor under the Federal Acquisition Regulation.

Coverage under the Public Readiness and Emergency Preparedness (PREP) Act extends to Organization if it complies with the PREP Act and the PREP Act Declaration of the Secretary of Health and Human Services.<sup>7</sup>

9/14/2020 Page **3** of **8** 

35

<sup>&</sup>lt;sup>5</sup> The disposal process for remaining unused COVID-19 Vaccine and adjuvant may be different from the process for other vaccines; unused vaccines must remain under storage and handling conditions noted in Item 7 until CDC provides disposal instructions; website URL will be made available.

<sup>&</sup>lt;sup>6</sup> https://vaers.hhs.gov/reportevent.html

<sup>&</sup>lt;sup>7</sup> See Pub. L. No. 109-148, Public Health Service Act §§ 319F-3 and 319F-4, 42 U.S.C. § 247d-6d and 42 U.S.C. § 247d-6e; 85 Fed. Reg. 15,198, 15,202 (March 17, 2020).



# SAMPLE CDC COVID-19 Vaccination Program Provider Agreement

Chief Medical Officer (or Equivalent)			
Last name	First name	Middle initial	
Cignoture		Data	
Signature:  Complete in CVMS		Date:	
Chief Executive Officer (or Chief Fiduciary)			
Last name	First name	Middle initial	
Signature:		Date:	
Complete in CVMS			
For official use only:  VTrckS ID for this Organization, if applicable:			
Vaccines for Children (VFC) PIN, if applicable: Other PIN (e.g., state, 317):			
IIS ID, if applicable:			
Unique COVID-19 Organization ID (Section A)*:			
*The jurisdiction's immunization program is required to create a unique COVID-19 ID for the organization named in Section A that			
includes the awardee jurisdiction abbreviation (e.g., an organization located in Georgia could be assigned "GA123456A"). This ID is			
needed for CDC to match Organizations (Section A) with one or more Locations (Section B). These unique identifiers are required even if there is only one location associated with an organization.			
if there is only one isocution associated with an organization.			

9/14/2020 Page 4 of 8 36



# SAMPLE

### Section B. CDC COVID-19 Vaccination Program Provider Profile Information

Please complete and sign this form for your Organization location. If you are enrolling on behalf of one or more other affiliated Organization vaccination locations, complete and sign this form for each location. Each individual Organization vaccination location must adhere to the requirements listed in Section A.

ORGANIZATION IDEN	ITIFICATION FOR INDI	VIDUAL LOCAT	TIONS			
Organization location	name:		Will ano	ther Organiza	ation location	order COVID-19
				for this site?		
Comp	lete in CVMS		□ Y	es; provide C	Organization n	ame:
				lo		
CONTACT INFORMAT	TION FOR LOCATION'S	PRIMARY COV	VID-19 VAC	CINE COORD	INATOR	
Last name:	First na	ame:	Midd	le initial:		
Telephone:		Email:				
CONTACT INFORMAT	ION FOR LOCATION'S	BACK-UP COV	ID-19 VAC	CINE COORD	NATOR	
Last name:	First n	ame:	Midd	le initial:		
Telephone:		Email:				
ORGANIZATION LOCA	ATION ADDRESS FOR I	RECEIPT OF CO	VID-19 VA	CCINE SHIPM	ENTS	
Street address 1:	Street	address 2:				
City:	County:		State:	ZII	P:	
Telephone:			Fax:			
ORGANIZATION ADD	RESS OF LOCATION W	HERE COVID-1	9 VACCINE	WILL BE ADI	MINISTERED (	IF DIFFERENT FROM
RECEIVING LOCATION	N)					
Street address 1:	Street	address 2:	>			
City:	County:		State:		ZIP:	
Telephone:	7 7 7		Fax:			
DAYS AND TIMES VA	CCINE COORDINATOR	S ARE AVAILA	BLE FOR RE	CEIPT OF CO	VID-19 VACCI	NE SHIPMENTS
Monday	Tuesday	Wedn	esday	Thur	sday	Friday
AM:	AM:	AM:		AM:	А	ιM:
PM:	PM:	PM:		PM:	P	M:
For official use only: VTrckS ID for this location	, if applicable:		Vaccines for (	Children (VFC) P	IN, if applicable:	9 
IIS ID, if applicable:	Unique COVID-1	9 Organization ID	(from Section	n A):	Unique l	Location ID**:
W 10 1000						
**The jurisdiction's immu	nization program is require	ed to create an ad	lditional uniqu	ie Location ID fo	or each location	completing Section B. The
	wardee jurisdiction abbrev					
three locations (main local GA123456B3.	ition plus two additional) c	ompleting section	B, they could	l be numbered o	is GA123456B1,	GA123456B2, and

9/14/2020 Page **5** of **8** 



# SAMPLE

### **CDC COVID-19 Vaccination Program Provider Profile Information**

COVID	-19 VACCINATION PROVIDER TYPE FOR THIS LOCAT	ION (SE	LECT ONE)
	Commercial vaccination service provider		Pharmacy – chain
	Corrections/detention health services		Pharmacy – independent
	Health center – community (non-Federally Qualified		Public health provider – public health clinic
	Health Center/non-Rural Health Clinic)		Public health provider – Federally Qualified Health
	Health center – migrant or refugee		Center
	Health center – occupational		Public health provider – Rural Health Clinic
	Health center – STD/HIV clinic		Long-term care – nursing home, skilled nursing
	Health center – student	898	facility, federally certified
	Home health care provider		Long-term care – nursing home, skilled nursing
	Hospital	_	facility, non-federally certified
	Indian Health Service		Long-term care – assisted living
	Tribal health		Long-term care – intellectual or developmental
	Medical practice – family medicine	H	disability
	Medical practice – pediatrics		Long-term care – combination (e.g., assisted living and nursing home in same facility)
	Medical practice – internal medicine	50	Urgent care
	Medical practice – OB/GYN	7.7	Other (Specify: )
	Medical practice – other specialty		Other (Specify.
SETTIN	NG(S) WHERE THIS LOCATION WILL ADMINISTER CO	VID-19 \	ACCINE (SELECT ALL THAT APPLY)
	Childcare or daycare facility	358	Pharmacy
	College, technical school, or university		Public health clinic (e.g., local health department)
	Community center		School (K – grade 12)
	Correctional/detention facility		Shelter
	Health care provider office, health center, medical		Temporary or off-site vaccination clinic – point of
	practice, or outpatient clinic		dispensing (POD)
	Hospital (i.e., inpatient facility)	- Q	Temporary location – mobile clinic
	In-home		Urgent care facility
	Long-term care facility (e.g., nursing home, assisted		Workplace
	living, independent living, skilled nursing)		Other (Specify:)
1222	NAME OF THE PROPERTY OF THE PR	V essy	TRANSPORTION
The state of the state of	DXIMATE NUMBER OF PATIENTS/CLIENTS ROUTINEL	28	905
Numb		1 100	"0" if the location does not serve this age group.)
	□ Unkno	own	
Numb	er of adults 19 – 64 years of age:	(Enter	"0" if the location does not serve this age group.)
	□ Unkno	own	
Numb	er of adults 65 years of age and older:		"O" if the location does not serve this age group.)
	□ Unkne	Manual Children	
P. D.	er of unique patients/clients seen per week, on avera	age:	
St. 50 September	known		
	t applicable (e.g., for commercial vaccination service	provide	rs)
	ENZA VACCINATION CAPACITY FOR THIS LOCATION	34 - 430 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 120 - 1	
Numb	er of influenza vaccine doses administered during the		
	(Enter "0" if no influenza vaccine doses were administer	ed by this	location in 2019-20)
☐ Un	known		

9/14/2020 Page **6** of **8** 38



# SAMPLE

### **CDC COVID-19 Vaccination Program Provider Profile Information**

POPU	LATION(S) SERVED BY THIS LOCATION (SELECT ALL 1	THAT APPLY)
	General pediatric population	
	General adult population	
	Adults 65 years of age and older	
	Long term care facility residents (nursing home, ass	sisted living, or independent living facility)
	Health care workers	
	Critical infrastructure/essential workers (e.g., educ	cation, law enforcement, food/agricultural workers, fire
	services)	
	Military – active duty/reserves	
	Military – veteran	
	People experiencing homelessness	
	Pregnant women	
	Racial and ethnic minority groups	
	Tribal communities	
	People who are incarcerated/detained	
	People living in rural communities	
	People who are under-insured or uninsured	
	People with disabilities	
	People with underlying medical conditions* that ar	e risk factors for severe COVID-19 illness
	Other people at higher-risk for COVID-19 (Specify:	
DOES	YOUR ORGANIZATION CURRENTLY REPORT VACCIN	NE ADMINISTRATION DATA TO THE STATE, LOCAL, OR
	TORIAL IMMUNIZATION INFORMATION SYSTEM (III	
	Yes [List IIS Identifier:]	
	No	
	Not applicable	
		ine administration data to the jurisdiction's IIS or other
	ated system as required:	
If "No	applicable," please explain:	
ESTIM	ATED NUMBER OF 10-DOSE MULTIDOSE VIALS (MD	DVs) YOUR LOCATION IS ABLE TO STORE DURING PEAK
The second second second		OR INFLUENZA VACCINE SEASON) AT THE FOLLOWING
	ERATURES:	
Refrige	erated (2°C to 8°C):	☐ Approximately additional 10-dose MDVs
Frozen	(-15° to -25°C):   No capacity	☐ Approximately additional 10-dose MDVs
Ultra-f	rozen (-60° to -80°C):	☐ Approximately additional 10-dose MDVs
STORA	AGE UNIT DETAILS FOR THIS LOCATION	
	and/model/type of storage units to be used for	I attest that each unit listed will maintain the appropriate
	g COVID-19 vaccine at this location:	temperature range indicated above: (please sign and
	mple: CDC & Co/Red series two-door/refrigerator	date)
2.		Complete in CVMS
3.		Medical/pharmacy director or location's vaccine coordinator signature
4.		Complete in CVMS
5.		Date
		BYC SKEEDIN

9/14/2020 Page **7** of **8** 

 $<sup>^*\</sup>underline{\text{https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-increased-risk.html}$ 



# SAMPLE CDC COVID-19 Vaccination Program Provider Profile Information

Provider Name	Title	License No.
mplete in CVMS		

Page 8 of 8 9/14/2020



### <u>Appendix 40 – Vaccine Letter to County Leaders</u>



## STATE OF NORTH CAROLINA DEPARTMENT OF HEALTH AND HUMAN SERVICES

ROY COOPER MANDY COHEN, MD, MPH
GOVERNOR SECRETARY

February 12, 2021

#### Dear County Leaders:

On Wednesday, Governor Cooper and I announced plans for how the state will move to Group 3 for COVID-19 vaccines. Because vaccine supply is still limited and the Group 3 population of frontline essential workers is so large, the state will move to the next group gradually. Therefore, we will begin with anyone working in child care or in PreK – 12 schools starting on February 24<sup>th</sup> and plan to move to additional frontline essential workers on March 10<sup>th</sup>. Some vaccine providers may not be ready to open to frontline essential workers on these dates if they are still experiencing high demand for vaccines in Groups 1 and 2.

Beginning on February 24<sup>th</sup>, those working in child care and schools, such as teachers, bus and van drivers, custodial and maintenance staff, and food service workers, will be eligible for vaccines. This includes staff in child care centers and homes, Head Start Programs, Preschool and PreK programs, traditional public schools, charter schools and private schools. (See Deeper Dive for additional detail.)

While staff in child care settings and PreK-12 schools will be eligible starting February 24<sup>th</sup> that <u>does not guarantee</u> they will get an appointment or get vaccinated between February 24<sup>th</sup> and March 10<sup>th</sup> because of very limited supply. However, the two-week period between February 24<sup>th</sup> and March 10<sup>th</sup> will allow for a more measured opening of the frontline essential workforce group.

NCDHHS is developing operational guidance to support child care and school staff in accessing vaccines. However, current prevention measures will not change. Schools can and should be providing in-person instruction. Under robust safety measures, all students can be in classrooms, with middle and high school students also following six-feet social distancing protocols.

North Carolina is currently vaccinating people in Groups 1 and 2, which include health care workers, long-term care staff and residents, and people 65 and older. Many local vaccine providers do not have enough vaccines to meet the needs of the currently eligible Groups. In the coming weeks, some providers will continue to vaccinate only these groups, whereas others may be ready to start vaccinating school and child care staff on February 24<sup>th</sup>. Whether vaccine providers can vaccinate school and child care staff will depend on vaccine supply and whether they are still experiencing high levels of demand from Groups 1 and 2.

We look forward to working with you to develop operational guidance to support vaccine distribution to child care and school staff. Thank you for your ongoing partnership.

Sincerely,

Mandy K. Cohen, MD, MPH

Secretary

WWW.NCDHHS.GOV
TEL 919-855-4800 • FAX 919-715-4645
LOCATION: 101 BLAIR DRIVE • ADAMS BUILDING • RALEIGH, NC 27603
MAILING ADDRESS: 2001 MAIL SERVICE CENTER • RALEIGH, NC 27699-2000
AN EQUAL OPPORTUNITY / AFFIRMATIVE ACTION EMPLOYER



# <u>Appendix 45 – CVMS Organization Portal email template for vaccine providers to use to invite organizations</u>

Organization Portal Template Email (Vaccine Providers to Send to Organization Point of Contact). Details about Template Email:

**Sender:** Vaccine providers partnering with an Organization/Employer to use the CVMS Organization Portal

**Recipient:** Organization points of contact (e.g., superintendents and/or their designee, CCR&R point of contact) who are invited by vaccine provider to use the Organization Portal and will be responsible for bulk upload of employee information

**Purpose:** Explains what to expect in CVMS, common issues/questions that might arise from a user who has not used CVMS before

**Instructions before sending:** Customize the highlighted information below.

**Email Subject:** Please use Organization Portal to upload employees to register for vaccination Hello,

Thank you for your support and patience as we partner to use the COVID-19 Vaccine Management System (CVMS) Organization Portal.

North Carolina has created an Organization Portal so employers and organizations can register employees or members to receive the COVID-19 vaccine at the appropriate time. Employers/organizations can upload an Excel (CSV) file to facilitate registration of eligible employees. Once uploaded, employees will receive a private and secure email to complete the registration process ahead of getting their vaccine – saving time and paperwork. Registration does not guarantee an appointment or that vaccine is available.

[Insert vaccine provider name] will add your organization into CVMS, so you can use the CVMS Organization Portal. We will also add you as the point of contact for your organization. You will receive an email shortly from <a href="mailto:nccvms@dhhs.nc.gov">nccvms@dhhs.nc.gov</a> that provides your login information for the Organization Portal and specific instructions on next steps (see sample email in screenshot below).





### What You Should Expect as the Organization Point of Contact

- 1. [Insert name of vaccine provider] will develop a plan with your organization to vaccinate employees.
- 2. [Insert name of vaccine provider] will add your organization to CVMS and will add you as the Organization Point of Contact in CVMS.
- 3. Please check your email and confirm you have received an invitation from <a href="mailto:nc.gov">nccvms@dhhs.nc.gov</a> to access the CVMS Organization Portal. If you experience a delay in receiving the email, please check your spam folder. If the issue seems to be occurring for other people in your organization as well, your organization's IT department may be able to help. A link to the NCDHHS Help Desk Portal and a phone number for support can also be found at the bottom of this letter.
- 4. We strongly recommend you use the email template, Organization Portal Email Template\_Organization POC to Employees, in Vaccine Provider Guidance Appendix 46) to communicate with your employees/members prior to completing the bulk upload process in CVMS. The email template covers what employees/members should expect about registration, how to schedule a vaccination appointment, and actions they will need to take. You can customize the template to include information that is specific to your employees, such as details and logistics on the day of the vaccination appointment or event.



5. After you have communicated with your employees/members using the email template above, you can upload your list of employees/members in the CVMS Organization

**Portal.** The bulk upload template can be downloaded directly from the CVMS Organization Portal and is also posted on the <a href="NCDHHS website">NCDHHS website</a>. Step-by-step instructions and tips are outlined in the <a href="CVMS">CVMS</a>
Organization Portal User Guide. Please note that you will need the first names, last names, and email addresses (enter in the order shown in the bulk upload template) of all employees/members you wish to upload into the CVMS Organization Portal. We strongly recommend reading the user guide and attending a training before you complete the bulk upload process. Please check the NCDHHS website for a <a href="Listing of all upcoming trainings">Listing of all upcoming trainings</a>, with information on how to join.

- 6. Once you finish the bulk upload process, all uploaded employees will receive an email notifying them that they can complete COVID-19 vaccine registration in the COVID-19 Vaccine Portal.
- 7. After completing registration, employees will be able to schedule their vaccine appointments through the method that you have jointly agreed upon. Registration in the COVID-19 Vaccine Portal is not required for vaccination. If an individual does not have an email address, that person can be registered in the COVID-19 Vaccine Portal by the vaccine provider at the time of vaccination.

Please be on the lookout for emails from <a href="mailto:nc.gov">nccvms@dhhs.nc.gov</a>, which are from the NCDHHS team. These messages contain important guidance and announcements related to NC's fight against COVID-19 and the use of CVMS.

If you experience any issues using the CVMS Organization Portal to bulk upload employees, please submit a ticket in the <a href="CVMS Help Desk Portal">CVMS Help Desk Portal</a>. Select "Organization/Employer" and complete all required fields in the Vaccine Organization web form. The Provider and Organization Contact Center is also available Monday-Friday 7:00AM to 7:00PM ET and Saturday-Sunday 10:00AM-6:00PM ET. Call (877) 873-6247 and select option 8.

Thank you for your continued support, [Vaccine Provider]

# <u>Appendix 46 - CVMS Organization Portal email templates for organizations to use to inform</u> employees

Organization Portal Template Email (Organization Point of Contact to Send to Employees). Details about Template Email:

**Sender:** Organization Point of Contact (POC) who will be responsible for completing bulk upload of employee names and emails into CVMS Organization Portal

**Recipient:** Employees/members of an employer/organization whose name and email address will be bulk uploaded in the CVMS Organization Portal and will be invited by email to complete their registration in the COVID-19 Vaccine Portal.

**Purpose:** What employees should expect in CVMS, completing registration, steps to get a vaccination appointment.

**Instructions before sending:** Customize the highlighted information below.

.....

**Email Subject:** Please complete your COVID-19 vaccine registration

Dear employees:

You'll soon be able to take a tested, safe and effective COVID-19 vaccine. The vaccines help prevent COVID-19 and are effective in preventing hospitalization and death, with no serious safety concerns noted in the clinical trials. They are free of charge to all North Carolina residents.



[Insert organization/employer name] is working with [Insert vaccine provider name] to get employees preregistered for the COVID-19 vaccine. As part of registration, a representative from [Insert
organization/employer name] will upload employees' first names, last names, and email addresses to North
Carolina's COVID-19 Vaccine Management System (CVMS). If you haven't already, you will receive an email
that will allow you to register for the vaccine before coming in for your vaccination appointment, so that the
process is faster when you show up for your vaccination.

Please follow the steps below to complete your COVID-19 vaccine registration in the COVID-19 Vaccine Portal.

### **COVID-19 Vaccine Portal & COVID-19 Vaccine Registration Instructions**

- 1. You will receive an email from nccvms@dhhs.nc.gov inviting you to pre-register on the COVID-19 Vaccine Portal. Click the link in the email and follow the instructions to reset your password. You may need to check your spam folder.
- 2. Follow the instructions to change your COVID-19 Vaccine Portal Password
- 3. Complete the COVID-19 Vaccination Registration before your appointment to get your first vaccine dose.
  - a. Enter your contact and demographic details
  - b. Answer a few questions related to vaccine eligibility

To see more detailed registration instructions with screenshots, please visit the <a href="COVID-19 Vaccine Portal User Guide">COVID-19 Vaccine Portal User Guide</a>.

If you experience a delay in receiving an email invitation to pre-register, check your spam folder. If you still do not see an email, contact [Sender should customize this message based on who uploaded employees/members].

### Important things to know about registration:

- Your privacy and personal information will be protected at all times.
- If you do not have an email address or did not complete the registration steps, you can still complete registration in-person when you arrive for a vaccine appointment you do not need to pre-register in order to be able to get a vaccination.
- If you do not wish to get the vaccine at this time, you do not need to take any additional steps.

Follow instructions below to sign up for a vaccination appointment.

[Sender should customize this message to include steps for how employees can get vaccinated, based on your plan with your vaccine provider to vaccinate employees.] You will still need to take the additional action of getting an appointment by taking the following steps: [insert steps employee should take to get an appointment or when/where employees should arrive for a scheduled vaccine event] Please note, as vaccine is still limited in supply, registering in the COVID-19 Vaccine Portal does not guarantee immediate vaccination for everyone and you may have to wait.

For other COVID-19 related questions, you may contact the COVID-19 Vaccine Help Center at 888-675-4567 Monday through Friday from 7:00 AM until 7:00 PM ET, and on Saturday and Sunday from 8:00 AM until 4:00 PM ET. The <a href="CVMS Help Desk Portal">CVMS Help Desk Portal</a> is also available for submitting questions and requests for support (select Vaccine Recipient).

[Sender's choice of close]
[Name]



### Appendix 51 - Strategies to Fill COVID-19 Vaccine Appointments



DEVELOPING PARTERSHIPS Prior to allocation

PLANNING: FILLING APPOINTEMENTS Once allocation is confirmed PRE-EVENT COMMUNICATION Fill any appointments that remain 1-3 days prior DURING THE EVENT Continue to fill appointments, and respond to no-shows

### **Developing Partnerships and Planning**

- Develop partnerships with local organizations and employers to help fill appointments. While
  providers are ultimately responsible for filling appointments quickly and equitably, a community
  organization can be an important partner in achieving these goals.
  - a. See a list of organizations that have already volunteered to help support vaccine events here
  - b. Consider partners with strong ties in your communities such as faith-based organizations, <u>Local NAACP chapters</u>, local <u>HBCUs</u>, <u>Community Health Workers</u>, <u>homeless shelters</u>, partners that serve homebound persons
    - (e.g. homebound health providers, Meals on Wheels, senior living), and other community based organizations (e.g. local United Way, food pantries, etc), community civic clubs (e.g. Rotary, Kiwanis, Lions clubs), and local colleges or universities.
  - c. Work with employers to vaccinate their employees.
    - i. Contact a NCDHHS case manager to find out if an employer near you needs vaccinations.
    - Reach out directly to local employers, local <u>school systems</u>, <u>charter schools</u>, and <u>private schools</u>, Local <u>chambers of commerce</u>, or organizations serving farmworkers, such as <u>farmworker health</u> <u>clinics in NC</u>, <u>NC Cooperative Extension Offices</u>, <u>AMEXCAN</u>, <u>NC Field</u>, <u>North Carolina Migrant</u> <u>Education Program</u>, <u>East Coast Migrant Head Start</u>
- Host vaccination Q&As with community partners or employers to address questions and concerns people may have before booking appointments. Key resource: Vaccine 101.



- As you plan your vaccine event, consider how to make the site easily accessible. Choose a trusted familiar location and include weekend and evening hours. If the event is accessible through public transportation, publicize those options, use free funding for public transit, and use free rides through Ride United NC.
- 4. Support language access to your event.
  - i. Offer bilingual scheduling. The state scheduling tool is available in both English and Spanish.
  - ii. **Include bilingual staff or volunteers from partner organizations** to help interpret for patients for whom English is not their first language.
  - iii. **Partner with local organizations** who can help promote the event in different languages, and/or provide bilingual staff or volunteers to help with the event.
  - iv. Ensure signage is clear and in multiple languages about where to enter, stand in line, etc.
  - v. Contact <a href="mailto:communication.access@dhhs.nc.gov">communication.access@dhhs.nc.gov</a> if you need help connecting with language access resources

### Planning: Filling appointments

- 5. Make it easy for people to find your clinic and schedule appointments
  - a. Have an easy way to schedule appointments online. You can use the CVMS Scheduling tool for free, which is available in both English and Spanish. See instructions here.
  - b. Give clear instructions on how to sign up for appointments or show up for walk-ins. Include those instructions in all of your communication, outreach, and promotional materials.
  - c. Be clear about when you're scheduling for first doses, and when you're scheduling for second doses.
  - d. Make sure you are listed on the statewide vaccine site locator (Myspot.nc.gov). To add yourself to the site locator or edit any information, see the instructions <u>here</u>
- 6. Promote your clinic or event on social media, websites, and via local businesses and media outlets (local news channels, e-newsletters). Use communications resources from the <u>Communications Toolkit</u> to get you started.
  - a. You can send a tailored text or email blast out about your event to the <u>DHHS Vaccine ListServ</u> in your county, which is a listserv of people who have signed up for vaccine updates, or through your <u>local health department</u> to promote your event to persons who are already listed in the state contact tracing software
  - b. NCDHHS will make customized materials to promote your event. Request them using this link.
- 7. Work with Partners to schedule appointments
  - a. Work with trusted community partners, particularly among historically marginalized populations to reach
    - to their networks and book appointments. Partners can:
    - i. Schedule appointments share access to your scheduling tool or create a dedicated scheduling link for partners to use. Tell partners how many slots you are trying to book.
    - ii. Promote appointments ask partner organizations to text, call, or promote the available appointments
      - in-person. You can create flyers, or draft emails or texts for them to distribute to their networks.
  - b. Reach out directly to employers that you have partnered with to schedule appointments
  - c. Work with the employer to register workers to get vaccinated, as many workers cannot call to make an appointment.



- 8. Make a Standby list to fill appointments in the case of cancellations or no-shows
  - a. If you fill appointments before the date of the event, **open up a "standby list"** and gather peoples contact information. You can use this list to fill appointments if people had to cancel or didn't show up. Invite individuals, employers, local businesses, or community organizations who were unable to get an appointment or scheduled at a later date to be on the standby list.

### Pre-event communication: Filling appointments that are still open

- 9. **Push out information about the vaccine event** including the link or phone number to schedule appointments again—let people know that there are available appointments.
  - a. Notify local partners and give them a text, flyer, or email they can use to notify their networks that appointments are available.
  - b. Contact people registered for appointments and encourage them to bring a friend.
  - c. Call radio stations and local newspapers in your area—ask if they will promote the event. Many will be able to promote or even send DJ's to your vaccine location for free, or minimal cost.
  - d. Contact DHHS to send out a text or email blast to their Vaccine ListServ. The listserv has more than 770,000 contacts on it and can be filtered by county. To request an email or text fill out this form
- 10. **Contact people and organizations on the standby waiting list** to notify them that there are appointments available to ensure no doses are wasted.

### **During the Event**

- 11. Ensure people are not turned away
  - a. Do not request people show a government-issued ID like a driver's license. Providers should not turn away individuals who cannot show identification. this can be a barrier to some historically marginalized populations like persons experiencing homelessness, immigrant populations, and older minority populations
  - b. Add people to the standby list if a person comes to the event and does not have an appointment and there are not slots available. Check every hour to see if you have no shows, so you can allow someone without an appointment to get their vaccine.
- 12. Consider promoting that you are taking walk-ups and be staffed appropriately to handle walk-up traffic.
- 13. Schedule second dose appointments (if needed) before individual leaves the vaccine clinic.

